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ABSTRACT 15 
Despite a long history of incorporating steroids into silicone elastomers for drug delivery 16 
applications, little is presently known about the propensity for irreversible drug binding in these 17 
systems. In this study, the ability of the contraceptive progestin levonorgestrel to bind 18 
chemically with hydrosilane groups in addition-cure silicone elastomers has been thoroughly 19 
investigated. Cure time, cure temperature, levonorgestrel particle size, initial levonorgestrel 20 
loading and silicone elastomer type were demonstrated to be key parameters impacting the 21 
extent of levonorgestrel binding, each through their influence on the solubility of levonorgestrel 22 
in the silicone elastomer. Understanding and overcoming this levonorgestrel binding 23 
phenomenon is critical for the ongoing development of a number of drug delivery products, 24 
including a multi-purpose technology vaginal ring device offering simultaneous release of 25 
levonorgestrel and dapivirine – a lead candidate antiretroviral microbicide – for combination 26 
HIV prevention and hormonal contraception. 27 
 3 
1. Introduction 28 
Silicone elastomers have been widely used in controlled release drug delivery applications since 29 
Dzuik and Cook first demonstrated in 1966 that various steroid molecules were capable of 30 
effectively permeating and releasing from silicone rubber capsules subcutaneously implanted in 31 
ewes [1]. Numerous steroid-releasing silicone elastomer devices, including subdermal implants, 32 
vaginal rings and intrauterine systems, have since reached market (Table 1). The past ten years 33 
have seen considerable interest in silicone elastomer vaginal ring technology for controlled 34 
release of antiretroviral (ARV) drug molecules for prevention of sexual transmission of human 35 
immunodeficiency virus (HIV) (Table 1) [2–9]. The International Partnership for Microbicides 36 
(IPM) and the Microbicide Trial Network (MTN) are currently in Phase III clinical trials in Africa 37 
with a matrix-type silicone elastomer vaginal ring developed by IPM. This ring device provides 38 
controlled release of dapivirine (Figure 1A), a non-nucleoside reverse transcriptase inhibitor, 39 
over 28 days and has already been shown to be safe and well tolerated in vivo. If successful, the 40 
dapivirine ring will likely provide both further impetus and a viable technology platform for 41 
development of multi-purpose prevention technologies (MPTs) aimed at combining HIV 42 
prevention with prevention of unintended pregnancy and prevention/treatment of other 43 
sexually transmitted infections (STIs) through use of a single formulation or drug-device 44 
combination product [10–13]. Many of the MPT products currently undergoing development 45 
have prioritised use of levonorgestrel (Figure 1A) as the contraceptive hormone component, 46 
based on its historical record of safety and efficacy [12–14]. 47 
  48 
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Table 1. Controlled release drug delivery devices for humans that use silicone elastomer as the rate controlling material. Marketed 49 
products (current or previous), discontinued development products and products presently undergoing clinical testing are included. 50 
VR – vaginal rings 51 
Product name Product type Drug(s) Indication / duration of action  Developer Stage 




subdermal implant levonorgestrel female contraception / 5 years Population Council Marketed  
Mirena® reservoir-type intrauterine system levonorgestrel female contraception / 5 years Bayer Marketed 
Skyla® reservoir-type intrauterine system levonorgestrel female contraception / 5 years Bayer Marketed 
Femring® reservoir-type VR 17β-estradiol-3-acetate estrogen replacement therapy / 3 months Warner Chilcott Marketed 
Estring® reservoir-type  VR 17β-estradiol estrogen replacement therapy / 90 days Pfizer Marketed 
Progering® matrix-type VR progesterone female contraception / 1 year Population Council Marketed (South America only) 
Fertiring® matrix-type VR progesterone in vitro fertilization / hormone replacement therapy / 3 months Population Council Marketed 
– matrix-type VR progesterone luteal phase support Italfarmaco Phase I/II 
– matrix-type VR progesterone luteal phase support TEVA Discontinued 
_ reservoir-type VR oxybutynin overactive bladder TEVA Discontinued 
– reservoir-type VR nestorone and ethinyl estradiol female contraception Population Council Phase III 
– matrix-type VR dapivirine HIV prevention / 30 days IPM Phase III 
– matrix-type VR dapivirine and maraviroc HIV prevention / 30 days IPM Phase I 
– matrix-type VR dapivirine and levonorgestrel HIV prevention / 90 days IPM Phase I 
 52 
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Silicone elastomers for use in medical and pharmaceutical applications are prepared through 53 
the chemical crosslinking of functionalised, linear, polydimethylsiloxane molecules. The most 54 
important chemical crosslinking mechanisms involve either condensation-cure or addition-cure 55 
chemistries. Condensation-cure systems involve the tin-catalysed reaction between hydroxy-56 
terminated polydimethylsiloxane molecules and a tetraalkoxysilane, resulting in the formation 57 
of the cured elastomer and an alcohol by-product [15,16]. Although the chemistry of this 58 
silicone elastomer crosslinking reaction is generally compatible with a very wide range of 59 
chemical functional groups, the alcohol produced can be problematic when the incorporated 60 
drug(s) is highly soluble in the alcohol [17,18]. Crosslinking of addition-cure silicone elastomer 61 
systems relies on the platinum-catalysed hydrosilylation reaction between hydride- and vinyl-62 
functionalised polydimethylsiloxane molecules (Figure 1B). No by-product is formed with this 63 
reaction. However, the platinum catalyst is particularly sensitive to poisoning by certain 64 
chemical functional groups, most notably organotin, organosulfur and certain amine containing 65 




Figure 1. A – Chemical structures of levonorgestrel and dapivirine. B – Addition-cure 68 
mechanism for silicone elastomers showing the platinum-catalysed hydrosilylation reaction 69 
between Si–H and vinyl groups. C – General hydrosilylation reaction between the Si–H groups in 70 
poly(methyl hydrogen silane) and alkenyl compounds. D – General hydrosilylation reaction 71 
between the Si–H groups in poly(methyl hydrogen silane) and alkynyl compounds.  72 
 73 
It is well established that small molecules containing ethylenic (C=C) and acetylenic (C≡C) 74 
functional groups can undergo hydrosilylation reaction with molecules containing hydrosilane 75 
(Si–H) groups (Figures 1C and 1D, respectively) [19–23]. In general, the alkyne hydrosilylation 76 
reaction catalysed by platinum proceeds at a faster rate compared to alkenes, and is less 77 
susceptible to many electronic and structural factors that may impede alkene hydrosilylation 78 
[19]. Given the large number of steroid molecules containing ethylenic or acetylenic functional 79 
groups that have been previously formulated in silicone elastomers, it is rather surprising that 80 
only a single article (a 1980 US patent) has reported the potential for covalent binding of such 81 
steroids to the silicone elastomer [24]. Furthermore, the patent states that the quantity of drug 82 
that reacts with the silicone elastomer is “negligible for the sustained drug release rate”. On the 83 
contrary, here we report that levonorgestrel, a common contraceptive progestin, reacts with 84 
addition-cure silicone elastomer systems such that a very significant fraction of the 85 
incorporated levonorgestrel can be irreversibly bonded to the silicone elastomer impacting 86 
levonorgestrel release rates. The extent of binding is dependent on the silicone elastomer cure 87 
conditions and the particle size of the levonorgestrel material used. Aside from recent U.S. 88 
patent applications by IPM [25,26], this issue has not been reported previously for 89 
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levonorgestrel, despite its long history of incorporation into addition-cure silicone elastomer 90 
drug delivery systems (Table 1).  91 
 9 
2. Methods and Materials 92 
2.1. Materials 93 
Medical grade, addition-cure silicone elastomers DDU-4320 and MED-4870, condensation-cure 94 
silicone elastomer MED-6382, and MED-360 silicone oil were supplied by NuSil Silicone 95 
Technology Inc. (Carpinteria, CA, USA). Micronized dapivirine was supplied by S.A. Ajinomoto 96 
OmniChem N.V. (Wetteren, Belgium). Micronised levonorgestrel was supplied by CHEMO 97 
Group (Saronno, Italy). Non-micronized and sieved fractions of non-micronized levonorgestrel 98 
(non-micronised levonorgestrel) were supplied by Tecoland (Irvine, CA, US) and CHEMO Group 99 
(Saronno, Italy); except where explicitly stated, non-micronised levonorgestrel in the text refers 100 
to material sourced from Tecoland. Particle size data (d10, d50 and d90; measured via laser 101 
diffraction) for each of the levonorgestrel materials was provided by the suppliers (Table 2). 102 
HPLC-grade acetonitrile, isopropanol and dichloromethane, and phosphoric acid (85% w/w in 103 
water) were purchased from Sigma Aldrich (Gillingham, UK). HPLC-grade water was obtained 104 
using a Millipore Direct-Q 3 UV Ultrapure Water System (Watford, UK). 19-norethindrone was 105 
supplied by LGM Pharma (Boca Raton, Florida, USA) and used as an internal standard for HPLC. 106 
Analytical grade potassium dihydrogen orthophosphate was obtained from VWR (Dublin, 107 
Ireland).  108 
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Table 2. Influence of levonorgestrel particle size on its recovery from 0.4% w/w levonorgestrel-109 
loaded DDU-4320 silicone elastomer slabs cured at 100 °C for 90 s. Each levonorgestrel 110 
recovery value is the mean of four replicates and reported errors denote standard deviations. 111 
levonorgestrel batch Particle size                              d90, d50, d10 (µm) 
% levonorgestrel 
recovery 
1 (micronized) 6.11, 2.18, 0.72 41.3 ± 6.5 
2 (sieved fraction) 294, 81, 5 56.7 ± 5.2 
3 (sieved fraction) 384, 170, 6 55.6 ± 2.8 
4 (non-micronized) * 542, 348, 156 98.4 ± 11.4 
* This non-micronized material was supplied by CHEMO. 112 
 113 
2.2. Manufacture of silicone rings and slabs 114 
Matrix-type, silicone elastomer vaginal rings containing 200 mg micronized dapivirine and 32 115 
mg levonorgestrel (either micronized or non-micronized) and measuring 57 mm overall 116 
diameter x 7.8 mm cross-sectional diameter were manufactured by reaction injection molding 117 
of active silicone elastomer mixes using a Babyplast 6/10P injection-molding machine in semi-118 
automatic mode fitted with custom, stainless steel, single-cavity injection molds. These rings 119 
were cured at 160˚C for 90 s. Briefly, the appropriate quantities of dapivirine and levonorgestrel 120 
powders were added to both Parts A and B of the addition-cure silicone elastomer system MED-121 
4870 and mixed at 3000 rpm for 3 min using a SpeedMixer DAC 150 FVZ-K (Synergy Devices, 122 
UK). These active premixes were stored at 4˚C until use. Prior to combining the premixes, they 123 
were first hand-mixed with a spatula for 30 s and then speedmixed for 120 s at 3000 rpm. Equal 124 
weights of Part A and Part B active premixes were then combined, handmixed for 30 s, 125 
speedmixed for 30 s at 3000 rpm, and then transferred to a 65 cc low-density polyethlyene 126 
Semco 220316 cartridge system (Polymer Systems Technology Ltd., Buckinghamshire, UK) that 127 
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operates with the dosing meter fitted to the Babyplast injection molder.  128 
 129 
Silicone elastomer slabs (20.0 × 30.0 × 2.0 mm) or vaginal rings containing levonorgestrel or 130 
dapivirine were also manufactured in a similar fashion using a custom, aluminium, multi-cavity 131 
mold fitted to a electrically-heated, laboratory-scale injection molding machine. For rings and 132 
slabs prepared using the DDU-4320 silicone elastomer (a low temperature cure system), cure 133 
time and temperature were varied between 1.5–120 min and 60–160˚C, respectively. For slabs 134 
prepared with the MED-4870 silicone elastomer (a high temperature cure system), cure time 135 
and temperature were varied between 1.5–120 min and 120–200˚C, respectively. 136 
Levonorgestrel-loaded silicone elastomer slabs were also prepared using condensation-cure 137 
MED-6382 silicone elastomer using cure conditions of 80°C / 5 min. For some silicone elastomer 138 
slabs, the drug powder was first dispersed in MED-360 silicone oil prior to preparing the silicone 139 
elastomer premixes. 140 
 141 
2.3. Quantification of levonorgestrel by HPLC 142 
Levonorgestrel concentrations were quantified by HPLC using a BDS Hypersil C18, 3 µm column 143 
(150 x 4.6 mm; Thermo Scientific, UK), fitted with an Analytical Guard Cartridge System 144 
(Phenomenex, UK), at 25˚C on a system comprising a Waters 1525 binary HPLC pump, 717 Plus 145 
autosampler, in-line degasser AF unit, and 2487 dual absorbance detector. Isocratic HPLC was 146 
performed with a mobile phase of 7.7 mM phosphate buffer, pH 3.0 and acetonitrile (55:45) at 147 
flow rate of 1.2 mL/min with detection at 240 nm. The retention times of norethindrone 148 
(internal standard) and levonorgestrel were 5.2 and 8.2 min, respectively. All chromatograms 149 
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were processed using the supplied Waters Breeze software.  150 
 151 
2.4. In vitro release testing of rings 152 
In vitro levonorgestrel release from vaginal rings (n=6) was assessed over a 15-day period. Each 153 
vaginal ring was placed into a glass flask containing 200 mL of isopropanol (IPA)/water mixture 154 
(1:1 volume ratio). This IPA/H20 mixture has been widely used for in vitro release testing of 155 
silicone elastomer vaginal rings, since it offers greater solvating power for poorly water-soluble 156 
drugs compared with aqueous media, such as simulated vaginal fluid [2–5,17]. The volumes of 157 
media for release testing were selected based on previously measured solubility values in 1:1 158 
IPA/water (LNG – 0.75 mg/mL at 25°C; DPV – 0.80 mg/mL at 37°C).  The flasks were sealed and 159 
placed in an orbital shaking incubator (Infors HT AGCH-4103; 37°C, 60 rpm, throw 25 mm). After 160 
24 h (± 15 min), each flask was removed from the incubator and a sample (2 mL) of the release 161 
medium was retained for HPLC analysis. The remaining release medium was discarded and 162 
replaced with fresh medium (100 mL IPA:H2O). This sampling procedure was continued on a 163 
daily basis, except weekends when 200 mL of release medium were added to the flasks each 164 
Friday so as to maintain sink conditions through the following Monday.  165 
 166 
2.5. Levonorgestrel content analysis of manufactured rings and slabs 167 
The total amount of levonorgestrel recoverable from silicone elastomer rings and slabs was 168 
determined using a solvent extraction method followed by quantification using HPLC. Each 169 
device was weighed, cut into approximately 2 mm sections, and placed in a 250 mL screw-top 170 
glass flask. 5 mL of a 2.5 mg/mL solution of 19-norethindrone in methanol (internal standard) 171 
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was added along with 95 mL of dichloromethane (extraction solvent). The flasks were placed in 172 
an orbital shaking incubator (37°C, 60 rpm, throw 25 mm) for 72 h. A 2 mL aliquot of the 173 
solution was evaporated to dryness and the residue reconstituted in 10 mL of methanol before 174 
being diluted ten-fold in a mixture of methanol and deionised water prior to analysis by HPLC. 175 
Control flasks containing known amounts of a levonorgestrel standard solution were also tested 176 
in each set of experiments.  177 
 178 
2.6. Drug extraction and swelling studies 179 
Cured silicone elastomer slabs containing 1% w/w loading of either dapivirine, micronised 180 
levonorgestrel or non-micronised levonorgestrel were manufactured, extracted with 181 
dichloromethane (100 mL), and then the resulting drug-depleted slabs swollen in n-hexane to 182 
assess cross-linking density [27]. A pictorial representation of the experimental method is 183 
shown in Figure 2. Briefly, drugs were weighed into the appropriate amounts of part A and part 184 
B silicone elastomer and speedmixed for 2 min. Part A and part B active mixes were then hand 185 
mixed (10 s), speedmixed (30 s), and then injection molded at 90 °C for 3 min. These slabs were 186 
individually weighed and the weights were recorded (W0). These slabs were then placed into 187 
screw-top glass flasks containing 45 mL of dichloromethane. 5 mL of 500 μg/mL methanolic 188 
solution containing norethindrone was added as an internal standard. The flasks were placed in 189 
a shaking orbital shaker (37 °C, 60 rpm, throw 25 mm) and the release medium was sampled 190 
(~5 mL) after a period of 72 h. Quantification of drug concentrations in the samples was 191 
performed using HPLC-UV. 192 
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 193 
Figure 2. Experimental protocol for hexane swelling experiments to assess crosslinking density 194 
in drug-loaded silicone silicone silicone slabs. 195 
 196 
Immediately after drug sampling, the swollen slabs were removed from the dichloromethane, 197 
wiped with tissue paper to remove any excess solvent, placed in a tightly closed flasks and 198 
weighed (W1). These slabs were then dried overnight in a fume hood at room temperature, 199 
followed by drying at 60°C for 1 h. The dry weights of the slabs were recorded (W2). The dried 200 
slabs were then placed in 50 mL of n-hexane. As before, the swollen slabs were weighed (W3), 201 
dried, and weighed again (W4). The amount of drug extracted, swelling ratio and total mass 202 
extracted from these silicone elastomer slabs in both solvents were calculated (Equations 1 – 203 
4). 204 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑟𝑟𝑟𝑟𝑟𝑟𝑆𝑆𝑟𝑟 𝑆𝑆𝑆𝑆 𝐶𝐶𝐶𝐶2𝐶𝐶𝑆𝑆2 = (𝑊𝑊1 −𝑊𝑊2) 𝑊𝑊2  ×  100             (1) 205 
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𝑀𝑀𝑟𝑟𝑀𝑀𝑀𝑀 𝑆𝑆𝑒𝑒𝑟𝑟𝑟𝑟𝑟𝑟𝑒𝑒𝑟𝑟𝑆𝑆𝑟𝑟𝑆𝑆 𝑆𝑆𝑆𝑆 𝐶𝐶𝐶𝐶2𝐶𝐶𝑆𝑆2 = (𝑊𝑊0 −𝑊𝑊2) 𝑊𝑊2  ×  100             (2) 206 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑟𝑟𝑟𝑟𝑟𝑟𝑆𝑆𝑟𝑟 𝑆𝑆𝑆𝑆 𝑆𝑆–ℎ𝑆𝑆𝑒𝑒𝑟𝑟𝑆𝑆𝑆𝑆 = (𝑊𝑊3 −𝑊𝑊4) 
𝑊𝑊4
 ×  100             (3) 207 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑟𝑟𝑟𝑟𝑟𝑟𝑆𝑆𝑟𝑟 𝑆𝑆𝑆𝑆 𝑆𝑆–ℎ𝑆𝑆𝑒𝑒𝑟𝑟𝑆𝑆𝑆𝑆 = (𝑊𝑊2 −𝑊𝑊4) 
𝑊𝑊2
 ×  100             (4) 208 
 209 
2.7. Oscillatory rheology 210 
Silicone elastomer samples containing 1, 5, 10, 15 and 20% w/w of dapivirine, micronised or 211 
non-micronised levonorgestrel were prepared by adding appropriate quantities of each drug 212 
powder to Parts A and B of silicone elastomer DDU-4320. Following mixing with a Speedmixer 213 
for 30 s, a sample of each silicone elastomer active mix (1.0 g) was placed onto the lower 214 
stationary plate of a TA instruments AR 1500 rotational rheometer, maintained at 25°C, and the 215 
upper plate (40 mm cross-hatch plate) was lowered to produce a gap between the plates of 216 
1000 µm. The time taken from loading of the sample to commencement of the experiment was 217 
typically less than 30 s. Each sample was heated to 80oC and maintained at that temperature 218 
for 15 min at 10 Hz oscillation frequency and the storage modulus monitored over 900 s, 219 
corresponding to the initial cure period for the silicone elastomer [28]. 220 
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3. Results and Discussion  221 
3.1. Particle size analysis 222 
Representative digital microscopy images of the four different levonorgestrel materials used in 223 
this study (one micronized material, two non-micronized and sieved fractions, and one non-224 
micronized and non-sieved material) are presented in Figure 3 and clearly illustrate visual 225 
differences in the particle size distributions. Quantitative measures of particle size (d10, d50 226 
and d90 values) for each of the four materials are also presented in Table 2.  227 
 228 
3.2. In vitro release testing of rings demonstrating bound levonorgestrel 229 
The mean daily release vs. time and mean cumulative release vs. root time profiles for MED-230 
4870 silicone elastomer matrix-type vaginal rings containing 200 mg micronized dapivirine and 231 
32 mg of either micronised levonorgestrel or non-micronised levonorgestrel and cured at 160 232 
°C for 90 s are presented in Figure 4. Dapivirine and non-micronised levonorgestrel are 233 
effectively released from the vaginal rings, with relatively high quantities of each drug released 234 
on Day 1 (~6000 μg and ~750 μg for dapivirine and levonorgestrel, respectively) followed by 235 
steadily declining release rates on subsequent days. Dapivirine release was very similar 236 
irrespective of the particle size of the levonorgestrel incorporated into the vaginal rings. The 237 
lower rate of release observed of non-micronised levonorgestrel from the vaginal rings 238 
compared with dapivirine is attributed to both its lower initial loading and its unique molecular 239 
permeability characteristics in the silicone elastomer. In general, the daily release profiles are 240 
typical of matrix-type vaginal rings containing solid drug dispersed within a non-degradable 241 
polymer matrix. The linear cumulative release vs. root time profiles (Figure 4C and 4D) confirm 242 
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root time (t1/2) kinetics, and are indicative of a permeation-controlled mechanism [29,30]. 243 
However, surprisingly, vaginal rings containing micronised levonorgestrel showed no drug 244 
release (Figures 4B and 4D). Repeat experiments confirmed that the correct quantity of 245 
micronised levonorgestrel was added to the silicone elastomer premixes and that no 246 
levonorgestrel release was observed (repeat data not shown). Based on scant evidence from 247 
the literature [24], we hypothesized that all 32 mg micronised levonorgestrel initially 248 
incorporated into the vaginal ring formulation had dissolved in the ring matrix and 249 
subsequently covalently bonded to the silicone elastomer via a hydrosilylation reaction (Figure 250 
1D) between the alkynyl (i.e. ethinyl) group in levonorgestrel (Figure 1A) and the Si–H groups in 251 
the silicone elastomer system (Figure 1B). This drug-binding hypothesis was supported by 252 
attempting to solvent-extract the levonorgestrel content from the vaginal rings; only 0.5% 253 
levonorgestrel was recovered for vaginal rings containing micronised levonorgestrel compared 254 
to 57.3% for non-micronised levonorgestrel vaginal rings. Dapivirine does not contain alkenyl or 255 
alkynyl functional groups (Figure 1A), and therefore is incapable of undergoing hydrosilylation 256 
reaction. 96.7% and 97.7% of incorporated dapivirine content was recovered from vaginal rings 257 
containing 200 mg dapivirine + 32 mg non-micronised levonorgestrel and 200 mg dapivirine + 258 
32 mg micronised levonorgestrel, respectively. In previous studies, complete recovery of 259 
dapvirine was also achieved with rings containing just 25 mg dapvirine, further confirming that 260 
dapvirine does not have the chemical functionality required to take part in the hydrosilylation 261 
reaction [4,18].     262 
 18 
 263 
Figure 3. Digital microscopy images at x 100 magnification of different particle size batches of 264 
levonorgestrel. A – d90 ≤ 6.11 µm, B – d90 ≤ 294 µm, C – d90 ≤ 384 µm and D – d90 ≤ 542 µm. 50 265 
μm size bars (⊢⊣) are presented bottom right in each photograph. Particle size values are also 266 




Figure 4. Mean daily release versus time and mean cumulative release versus root time profiles 270 
for matrix-type MED-4870 silicone elastomer vaginal rings containing 200 mg micronized 271 
dapivirine and 32 mg of either micronised levonorgestrel or non-micronised levonorgestrel 272 
(n=4). A – Daily dapivirine release vs. time plots. B – Daily levonorgestrel release vs time plots. C 273 
– Cumulative dapivirine release vs. root time plots. D – Cumulative levonorgestrel vs. root time 274 
plots. DPV – dapivirine. LNG – levonorgestrel. All rings were manufactured by injection molding 275 
at 160 °C for 90 s.  276 
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In order for effective drug release to occur from a silicone elastomer vaginal ring device, 277 
incorporated drug substances must permeate through the bulk of the silicone elastomer matrix. 278 
This permeation process can be considered as two discrete steps – dissolution of the drug in 279 
the silicone elastomer, followed by molecular diffusion of the solvated drug molecules through 280 
the silicone elastomer [30]. Both the degree of solubility and the rate of diffusion of drugs 281 
incorporated into silicone elastomers are temperature-dependent, and are expected to 282 
increase significantly at the high temperatures commonly used in injection molding 283 
manufacture of silicone elastomer vaginal rings. Solubility of the drug in the silicone elastomer 284 
matrix also increases the proportion of levonorgestrel molecules available for chemical binding 285 
via the hydrosilylation reaction. Thus, a rational explanation for the differences observed in 286 
release between micronised levonorgestrel and non-micronised levonorgestrel is that the 287 
micronized form of the drug exhibits faster rate of solubilization in the silicone elastomer at the 288 
160 °C manufacturing temperature (levonorgestrel melting point is 240 °C), such that a 289 
significant proportion of the levonorgestrel molecules subsequently react with the hydrosilane 290 
groups within the silicone elastomer. By contrast, the observation that vaginal rings containing 291 
32 mg non-micronised levonorgestrel exhibited significant levonorgestrel release was 292 
attributed to the reduced rate of dissolution associated with the larger levonorgestrel particles 293 
and, in turn, reduced levonorgestrel binding to the silicone elastomer. This observation concurs 294 
with the well-established principle of increased surface area leading to increased rate of 295 
dissolution, as expressed in the Noyes-Whitney equation [31]. 296 
 297 
3.3. Levonorgestrel binding studies 298 
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To explore this levonorgestrel-binding hypothesis further, additional solvent extraction 299 
experiments were conducted using levonorgestrel-loaded silicone elastomer slabs 300 
manufactured under different cure conditions. No levonorgestrel could be recovered by solvent 301 
extraction from MED-4870 silicone elastomer slabs containing 0.4% w/w micronised 302 
levonorgestrel manufactured at (i) various cure temperatures (120–200 °C) and a fixed cure 303 
time (10 min) (Figure 5A) and (ii) various cure times (1.5–120 min) and a fixed cure temperature 304 
(160 °C) (Figure 5B). By contrast, MED-4870 silicone elastomer slabs containing 0.4% w/w non-305 
micronised levonorgestrel produced measurable recovery of levonorgestrel by solvent 306 
extraction at all but the most extreme cure conditions (i.e. 200 °C at 10 min and 120 min at 160 307 
°C; Figures 6A and 6B, respectively). In fact, the non-micronised levonorgestrel MED-4870 slabs 308 
showed a clear trend of decreasing levonorgestrel recovery values as a function of both 309 
increasing cure temperature (Figure 5A) and increasing cure time (Figure 5B). These data and 310 
trends strongly support the hypothesis that levonorgestrel binding to the silicone elastomer 311 
system is dependent on its solubilization in the elastomer.  312 
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 313 
Figure 5. Influence of cure temperature and cure time on percentage recovery of micronized 314 
and non-micronised levonorgestrel from MED-4870 and DDU-4320 silicone elastomer slabs. 315 
Levonorgestrel loading for all samples was 0.4% w/w (equivalent to 32 mg in a human-sized 316 
vaginal ring device). Each data point represents the mean ± SD of 4 replicates. Error bars are 317 
often smaller than the plot symbols. 318 
 319 
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For the MED-4870 system, the highest recovery of levonorgestrel (66.2%) was measured for the 320 
non-micronised levonorgestrel slabs prepared at the 120 °C / 10 min cure condition (Figure 5A). 321 
This value is significantly below the range of acceptable assay values (85–115%) commonly 322 
specified for a Phase 1 product. Although higher values for levonorgestrel recovery could be 323 
achieved for the MED-4870 system by curing at lower temperatures, this would lead to 324 
significantly increased process cycle times such that scaled manufacture would be impractical. 325 
For example, in additional experiments, we demonstrated that MED-4870 silicone elastomer 326 
containing 0.4% w/w non-micronised levonorgestrel can be cured at 80 °C for 2.5 h to give a 327 
levonorgestrel recovery value of 86.2%. However, injection molding cycle times less than 2 min 328 
are preferable.  Reducing cure time is also not an option, since 90 s at 160 °C was the minimum 329 
cure condition required to produce a ring or slab device having sufficient mechanical properties 330 
for demolding.  331 
 332 
An alternative medical grade addition-cure silicone elastomer system, DDU-4320, was selected 333 
for testing based on its recommended low cure temperature characteristics. For silicone 334 
elastomer slabs containing micronised levonorgestrel and prepared at 60 °C for 7 min, 335 
levonorgestrel recovery was 75.6%, with values decreasing as cure temperature was increased 336 
(Figure 5C). However, no levonorgestrel recovery was obtained for cure temperatures 120 °C 337 
and above (Figure 5C). For the non-micronised levonorgestrel DDU-4320 samples, 338 
levonorgestrel recovery values were significantly higher (87.3% at 60 °C declining to 58.5% at 339 
160 °C; Figure 5C) compared to those for micronised levonorgestrel, mimicking the trend 340 
observed previously with the high temperature cure MED-4870 system. Selecting an 341 
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intermediate cure temperature of 100 °C for this DDU-4320 system, the effect of varying cure 342 
time has a greater influence on the micronised levonorgestrel compared with the non-343 
micronized material (Figure 5D). Importantly, the DDU-4320 slabs containing non-micronised 344 
levonorgestrel offered levonorgestrel recovery values close to the specified range for content 345 
assay / uniformity (90–110% label claim).  346 
 347 
For comparison, incorporation of 0.4% w/w micronised levonorgestrel and non-micronised 348 
levonorgestrel into MED-6382 silicone elastomer (a medical grade tin-catalysed condensation 349 
cure system) produced levonorgestrel recovery values of 98.9 and 100.8%, respectively. 350 
However, this condensation-cure silicone elastomer produces isopropanol as a by-product of 351 
the curing reaction. Both levonorgestrel and dapivirine are highly soluble in isopropanol, and 352 
therefore these condensation cure silicone elastomers are not preferred in order to avoid drug 353 
migration to the ring surface as isopropanol migrates to the vaginal ring surface and evaporates 354 
[17].   355 
 356 
Initially, the influence of levonorgestrel particle size on the extent of binding was tested using a 357 
single batch of micronised levonorgestrel and non-micronised levonorgestrel (Batches 1 and 4, 358 
respectively; Table 2; Figure 3; supplied by CHEMO). Two additional levonorgestrel materials 359 
(Batches 2 and 3) were sieved at source so that particles intermediate in size could be tested 360 
(Table 2). Silicone elastomer DDU-4320 slabs containing 0.4% w/w levonorgestrel were 361 
prepared at 100 ˚C for 90 s for each levonorgestrel batch. As expected, the levonorgestrel 362 
recovery values for these sieved levonorgestrel materials (56.7% and 55.6%; Table 2) lie 363 
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between the values for the previously tested non-micronised levonorgestrel and micronised 364 
levonorgestrel (98.4% and 41.3%, respectively; Table 2), further supporting the solubilisation 365 
hypothesis. The similarity in levonorgestrel recovery values for Batches 2 and 3 is most likely 366 
due to the equivalence in d10 values (despite the very different d90 and d50 values), since the 367 
fines are expected to contribute disproportionately to the overall surface area of the material.   368 
  369 
The percentage recovery of levonorgestrel from DDU-4320 silicone elastomer vaginal rings 370 
cured at 90˚C for 3 min increased (55.0 – 84.9%) as the loading amount of micronised 371 
levonorgestrel incorporated into the device was increased from 25 to 100 and 400 mg (Table 3). 372 
This trend is consistent with the proposed solubility hypothesis, since progressively smaller 373 
fractions of the total levonorgestrel loading are expected to dissolve and bind to the silicone 374 
elastomer as the levonorgestrel loading is increased. For the vaginal rings containing non-375 
micronised levonorgestrel, recoveries were close to 100% irrespective of levonorgestrel loading 376 
(Table 3). These recovery values are also slightly higher than those predicted based on the 377 
previous slab data (Figure 5). This is likely attributed to a temperature-insulating effect for drug 378 
particles located in the bulk of the vaginal rings, attributed to the larger volume and/or the 379 
smaller surface area-to-volume ratio associated with the vaginal ring devices compared with 380 
slabs. This insulation effect is further illustrated by the data presented in Supplementary 381 
Information in which reported non-micronised levonorgestrel recovery values were lower (but 382 
not significantly) for slabs compared with vaginal rings, and where both are manufactured 383 
under the same cure conditions.  384 
 385 
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Table 3. Percentage recovery levonorgestrel from matrix-type DDU-4320 silicone elastomer 386 
vaginal rings cured at 90 ˚C for 3 min and containing different amounts of micronized and non-387 
micronised levonorgestrel. Each levonorgestrel recovery value is the mean of four replicates 388 
and reported errors denote standard deviations. 389 
Levonorgestrel 
loading        
(mg, % w/w) 
% Levonorgestrel Recovery 
Non-micronized Micronized 
25, 0.3125 99.5 ± 2.3 55.0 ± 5.8 
100, 1.25 96.1 ± 6.9 71.1 ± 1.3 
400, 5.00 100.6 ± 8.0 84.9 ± 4.8 
 390 
 391 
MED-4870 and DDU-4320 addition-cure silicone elastomer systems are supplied as two-part 392 
kits. Both parts contain the silicone elastomer base material, which comprises various vinyl-393 
functionalised (Figure 1B) and hydroxy-terminated polydimethylsiloxane molecules. Part A also 394 
includes the platinum catalyst, while Part B also includes the poly(methylhydrosiloxane) 395 
component that ultimately reacts with the vinyl-functionalised polydimethylsiloxane molecules 396 
(Figure 1B). (Both parts also contain other components that are not pertinent to this 397 
discussion.) Therefore, it is conceivable that addition of levonorgestrel to only one of the parts 398 
might impact its propensity to bind when the two parts are subsequently mixed and cured. 399 
Percentage levonorgestrel recovery values for slabs made with either MED-4870 or DDU-4320 400 
and in which micronised levonorgestrel or non-micronised levonorgestrel is added to Part A 401 
only, Part B only or to both Parts are reported in Figure 6. For DDU-4320 slabs, the addition of 402 
levonorgestrel to one, other or both parts of the silicone elastomer system had no impact on 403 
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levonorgestrel recovery, although, as expected, differences in levonorgestrel recovery were 404 
observed for the micronized versus non-micronized materials (Figure 6B). However, addition of 405 
non-micronised levonorgestrel to Part B only of MED-4870 resulted in increased levonorgestrel 406 
recovery (57%) compared to adding it to Part A only (33%) or to both parts (30%) (Figure 6A). As 407 
previously observed, levonorgestrel recovery values were significantly higher for DDU-4320 408 




Figure 6. Influence of order of addition of levonorgestrel upon levonorgestrel recovery from 412 
MED-4870 and DDU-4320 silicone elastomer slabs (n=4). MED-4870 slabs were cured at 160 ˚C 413 
for 90 s. DDU-4320 slabs were cured at 100 ˚C for 90 s. Part A – levonorgestrel added only to 414 
Part A of the silicone elastomer prior to curing; Part B – levonorgestrel added only to Part B of 415 
the silicone elastomer only prior to curing; Part A & B – equal amounts of levonorgestrel added 416 
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to both parts prior to curing; NM – non-micronised levonorgestrel, M – micronised 417 
levonorgestrel. 418 
 419 
Silicone oils are sometimes used as dispersing agents for addition of drug powders to silicone 420 
elastomer systems. The impact of dispersing levonorgestrel in MED-360 silicone oil prior to 421 
manufacture of DDU-4320 silicone elastomer slabs was investigated for selected cure 422 
conditions. The results, presented in Supplementary Information, show that levonorgestrel 423 
recovery was typically 4–10% higher with use of the silicone oil. However, at the highest cure 424 
temperature tested (160 ˚C), no significant difference in levonorgestrel recovery was observed 425 
for either non-micronised or micronised levonorgestrel. 426 
 427 
In an additional set of experiments, silicone elastomer DDU-4320 slabs containing 1% w/w 428 
dapivirine, non-micronised levonorgestrel or micronised levonorgestrel and prepared via 429 
injection molding at 90 °C for 3 min were subjected to drug extraction via dichloromethane to 430 
measure drug recovery followed by swelling in hexane to determine the silicone elastomer 431 
crosslinking density. Similar to previous results, percentage drug recovery decreased in the 432 
order dapivirine (99.3%) > non-micronised levonorgestrel (87.6%) > micronised levonorgestrel 433 
(79.4%), reflecting the extent of reaction of each drug with the hydrosilane groups in the 434 
silicone elastomer system under the conditions of cure (Figure 7A). Following drug extraction, 435 
the slabs were dried and reweighed; the values for total percentage mass extracted are 436 
presented in Figure 7B. The ~5% mass loss observed for the control sample (containing no drug) 437 
was attributed to the extraction of non-reactive silicone oil components in the silicone 438 
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elastomer formulation. The same mass loss due to extraction of these oils was presumably also 439 
observed in each the drug-loaded samples, with any additional mass loss due to extraction of 440 
either non-bound drug or unreacted polydimethylsiloxane components. Interestingly, the 441 
highest extraction mass was observed for the micronised levonorgestrel slab, which is counter-442 
intuitive if only the propensity for the micronised levonorgestrel crystalline material to rapidly 443 
solubilize and undergo hydrosilylation reaction within the silicone elastomer is considered. 444 
However, these levonorgestrel molecules compete with the vinyl-functionalised 445 
polydimethylsiloxane molecules in the silicone elastomer system for reaction with the hydride-446 
functionalised polydimethylsiloxane molecules. In this way, the overall crosslink density is 447 
reduced in the silicone elastomer and there is increased opportunity for extraction of non-448 
reactive polydimethylsiloxane molecules. This effectively explains the trends in percentage 449 
mass extraction values (Figure 7B). An entirely similar trend is also observed for the percentage 450 
swelling values (in dichloromethane; Figure 7C), adding further support to the different impact 451 
of the various drug molecules on the silicone elastomer crosslinking density. Conventionally, 452 
crosslinking densities in silicone elastomer systems are measured by swelling samples in hexane 453 
rather than dichloromethane. Subsequent placement of the silicone elastomer slabs into 454 
hexane resulted in minimal additional mass loss (Figure 7D), and confirmed the previous trend 455 
in crosslinking density obtained with dichloromethane (compare Figures 8C and 7E). The plot of 456 
mean percentage mass extraction verses mean percentage swelling for the various silicone 457 




Figure 7.  Results of hexane swelling experiments to assess degree of crosslinking in silicone 461 
elastomer slabs after extraction of non-bound drug (n=4). nmLNG – non-micronised 462 
levonorgestrel; mLNG – micronised levonorgestrel; DPV – dapivirine. A – Percentage drug 463 
extraction in dichloromethane. B – Percentage mass extraction in dichloromethane. C – 464 
Percentage swelling in dichloromethane. D – Percentage mass extraction in dichloromethane. E 465 
– Percentage swelling in hexane. F - % Extraction (w/w) vs. swelling (w/w) in hexane. 466 
 467 
Given the observation that levonorgestrel covalently binds to the silicone elastomer during 468 
cure, oscillatory rheology was used to monitor changes in storage modulus (a measure of the 469 
stored energy, representing the elastic portion) of different non-micronised levonorgestrel, 470 
 32 
micronised levonorgestrel and dapivirine-loaded DDU-4320 silicone elastomer systems during 471 
the curing process. Consistent with previous reports [28], the storage modulus for each 472 
formulation increased with time, as exemplified by the rheograms for the non-micronised 473 
levonorgestrel formulations presented in Figure 8A and reflecting the increase in viscosity as 474 
cure progresses. However, the relationship between storage modulus and drug concentration is 475 
not simple. For example, for the non-micronised levonorgestrel formulations, storage modulus 476 
increased in the concentration rank order 1% < 5% ≅ 10% ≅ 15% < 0% < 20% (Figure 8B). 477 
This trend reflects the interplay between levonorgestrel’s ability to inhibit cure (via 478 
dissolution and reaction with the silicone elastomer) and to act as mechanical filler. For 479 
silicone elastomer formulations having relatively low levonorgestrel concentrations (e.g. 480 
1% w/w), cure inhibition predominates and the storage modulus is reduced significantly 481 
compared to the control formulation (0% levonorgestrel). However, at higher 482 
levonorgestrel loadings (e.g. 20% w/w), the cure inhibition effect is masked by the 483 
mechanical filler effect, as evidenced by storage modulus values significantly greater than 484 
the control formulation (Figure 8A). By plotting the value of the storage modulus at 800 s 485 
cure time versus drug concentration (Figure 8B), it is apparent that this complex interplay 486 
exists for both micronised levonorgestrel and non-micronised levonorgestrel. 487 
Unsurprisingly, the extent of cure inhibition is generally lower for the slower-dissolving 488 
(less prone to binding) non-micronised levonorgestrel samples. Dapivirine, on the other 489 
hand, lacks the chemical functionality to react with the silicone elastomer components and 490 
therefore does not exhibit the initial decline in storage modulus at low dapivirine 491 
concentrations compared with the non-medicated control. Instead, dapivirine acts solely as 492 
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a mechanical filler by increasing the storage modulus at relatively high dapivirine 493 
concentrations (Figure 8B).  494  495 
 496 
Figure 8. A – Oscillatory rheograms (storage modulus versus time) following the cure process 497 
for silicone elastomer samples containing different concentrations of non-micronised 498 
levonorgestrel. Plot symbols and error bars represent the mean and standard deviation of four 499 
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replicates. Similar rheograms were obtained for samples containing dapivirine and micronised 500 
levonorgestrel. B – Graph showing storage modulus at 800 s versus concentration of dapivirine, 501 
non-micronised levonorgestrel and micronised levonorgestrel. 502  503 
3.4. In vitro release of dapivirine and levonorgestrel from rings manufactured under optimised 504 
cure conditions   505 
Finally, armed with the knowledge that silicone elastomer type, cure temperature, cure time, 506 
levonorgestrel loading and levonorgestrel particle size all have a role to play in determining the 507 
extent of levonorgestrel binding, additional dapivirine+levonorgestrel matrix-type DDU-4320 508 
silicone elastomer vaginal rings were fabricated under processing conditions (94 ˚C cure 509 
temperature and 90 s cure time) selected to minimise levonorgestrel binding. The vaginal rings, 510 
all containing 200 mg micronized dapivirine and either 32, 48 or 64 mg non-micronised 511 
levonorgestrel were then tested for in vitro release and content assay. The 92-day in vitro 512 
dapivirine and levonorgestrel release profiles are presented in Figure 9. Dapivirine release 513 
characteristics over the first 15 days were entirely similar to those measured for the original 514 
MED-4870 vaginal rings (Figure 4). Dapivirine release on day 90 was in the range 325–342 μg for 515 
all vaginal ring formulations (Figure 9A) and dapivirine content assay values matched the label 516 
claim (99.3–100.4 %). For DDU-4320 vaginal rings manufactured using the optimised cure 517 
conditions, the mean day 1 amount of levonorgestrel released from the 200 mg dapivirine + 32 518 
mg non-micronised levonorgestrel vaginal ring was 1219 ± 37 μg (Figure 9B), a significant 519 
increase over the 732 ± 166 mean day 1 value for the MED-4870 rings (Figure 4B) and a 520 
consequence of a reduction in the extent of levonorgestrel binding. For the same DDU-4320 521 
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vaginal ring formulation, day 90 levonorgestrel release was 85 ± 5 μg (Figure 9B). The total 522 
percentage DPV release was approximately 33% (66 mg from initial 200 mg loading), while total 523 
percentage LNG release ranged from 54% – 64% depending on initial drug loading. 524 
  525 
These 92-day release values for both dapivirine and levonorgestrel bode well for a viability of a 526 
3-month MPT vaginal ring product offering both HIV prevention and contraception. As 527 
expected, increasing the non-micronised levonorgestrel loading within the DDU-4320 vaginal 528 
ring from 32 mg to either 48 mg or 64 mg produced increases in the levonorgestrel release rate 529 
proportional to the loading (Figure 9B and 9D). Critically, the percentage levonorgestrel 530 
recovery values in the content assay (93.0%, 94.4% and 95.9% for the 200/32, 200/48 and 531 
200/64 vaginal rings, respectively) now fall within the 90–110% label claim range. 532 
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 533 
Figure 9. In vitro daily release vs. time graph for release of micronised dapivirine and non-534 
micronised levonorgestrel from human-type, silicone elastomer, matrix vaginal rings into 1:1 535 
isopropanol/water. Cure conditions for these rings were 94 °C for 90 s. Daily release plot 536 
symbols and error bars (mostly not visible due to being smaller in size than the plot symbol) 537 
represent the mean and standard deviation of six replicates.  538 
 539 
4. Conclusions 540 
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Chemical reaction between the ethynyl functional group in levonorgestrel and the hydrosilane 541 
functional groups in addition-cure silicone elastomers takes place via the same hydrosilylation 542 
reaction used to cure the silicone elastomer, and leads to irreversible covalent binding of 543 
levonorgestrel molecules to the elastomer. The extent of levonorgestrel binding depends upon 544 
the processing conditions, including cure temperature, cure time, levonorgestrel particle size, 545 
levonorgestrel loading and the type of silicone elastomer. This API-binding phenomenon raises 546 
challenges for the future development of certain silicone elastomer drug delivery devices that 547 
incorporate drug molecules with similar chemically reactive functional groups, including a 548 
significant number of other steroid molecules.       549 
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